ORGO Q1 2021 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q1 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$103M+66.1% YoY

Gross Profit

$77M75.1% margin

Operating Income

$13M12.3% margin

Net Income

$10M9.7% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

-4.0%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$6M

Stock-Based Comp.

$698,000

Balance Sheet

Total Assets

$319M

Total Liabilities

$162M

Stockholders' Equity

$157M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$103M	$62M	+66.1%
Gross Profit	$77M	$43M	+79.5%
Operating Income	$13M	-$15M	+183.6%
Net Income	$10M	-$16M	+161.0%

Revenue Segments

Advanced Wound care

$91M88%

Surgical and Sports Medicine

$12M12%